nevirapina accord 400 mg comprimidos de liberacion prolongada efg
accord healthcare s.l.u. - nevirapina - comprimido de liberaciÓn prolongada - 400 mg - nevirapina 400 mg - nevirapina
nevirapina tarbis farma 400 mg comprimidos de liberacion prolongada efg
tarbis farma s.l. - nevirapina, anhidra - comprimido de liberaciÓn prolongada - 400 mg - nevirapina, anhidra 400 mg - nevirapina
nevirapina aurovitas 400 mg comprimidos de liberacion prolongada efg
aurovitas spain, s.a.u. - nevirapina - comprimido de liberaciÓn prolongada - 400 mg - nevirapina 400 mg - nevirapina
itraconazol cinfa 100 mg capsulas efg
laboratorios cinfa s.a. - itraconazol - cÁpsula dura - 100 mg - itraconazol 100 mg - itraconazol
itraconazol stada 100 mg capsulas duras efg
laboratorio stada s.l. - itraconazol - cÁpsula dura - 100 mg - itraconazol 100 mg - itraconazol
itragerm 50 mg capsulas duras
isdin s.a. - itraconazol - cÁpsula dura - 50 mg - itraconazol 50 mg - itraconazol
adempas
bayer ag - riociguat - hipertensión, pulmonar - antihipertensivos para la hipertensión arterial pulmonar - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. la eficacia se ha demostrado en un pah la población, incluyendo a las etiologías de la idiopático o hereditario hap o pah asociada con enfermedad del tejido conectivo. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
lorviqua
pfizer europe ma eeig - lorlatinib - carcinoma, pulmón no microcítico - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
atrison 500 mg
por tableta; emtricitabina 200.000000 mg; cobicistat 150.000000 mg; elvitegravir 150.000000 mg; fumarato de tenofovir alafenamida 11.200000 mg; - emtricitabina, tenofovir alafenamida, elvitegravir y cobicistat
stribild comprimido recubierto
gador - comprimido recubierto - elvitegravir 150 mg + cobicistat 150 mg + emtricitabina 200 mg + tenofovir 300 mg comprimido